Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Zhou, F. [1 ]
Wang, W. [2 ]
Xia, L. [2 ]
Dai, J. [2 ]
Wu, H. [1 ]
Yang, L. [1 ]
Gong, J. [3 ]
Chen, X. [4 ]
Xiong, Z. [5 ]
Liang, X. [6 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Radiochemotherapy Dept, Hepatobiliary Pancreas Abdominal Tumor, Wuhan, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Radiochemotherapy Dept, Gastrointestinal Tumor, Wuhan, Peoples R China
[3] Huangshi Cent Hosp, Med Oncol, Huangshi, Hubei, Peoples R China
[4] Henan Canc Hosp, Med Oncol, Zhengzhou, Peoples R China
[5] HuBei Canc Hosp, Gastrointestinal Surg, Wuhan, Peoples R China
[6] HuBei Canc Hosp, Dept Med, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612P
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [21] Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
    Li, Wenhua
    Chang, Jinjia
    Wang, Chenchen
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Metronomic irinotecan and standard FOLFIRI regimen as first-line chemotherapy in metastatic colorectal cancer (MCRC). Final results of phase II study
    Nardi, M.
    Azzarello, D.
    Del Medico, P.
    Giannicola, R.
    Falzea, A.
    Giuffre, C.
    Maisano, R.
    Panuccio, V.
    Raffaele, M.
    Zavettieri, M.
    Avallone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget Anne
    Strickland, Andrew
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan Thomas
    Boucher, Eveline
    Tichler, Thomas E.
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [25] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Keisuke Miwa
    Eiji Oki
    Yasunori Emi
    Hiroshi Saeki
    Tetsuya Kusumoto
    Yoshito Akagi
    Yutaka Ogata
    Hironori Samura
    Shoji Tokunaga
    Hiroshi Ishikawa
    Takaho Tanaka
    Susumu Sueyoshi
    Hidefumi Higashi
    Hiroyuki Matsuda
    Tetsuo Touyama
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2016, 21 : 110 - 117
  • [26] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Miwa, Keisuke
    Oki, Eiji
    Emi, Yasunori
    Saeki, Hiroshi
    Kusumoto, Tetsuya
    Akagi, Yoshito
    Ogata, Yutaka
    Samura, Hironori
    Tokunaga, Shoji
    Ishikawa, Hiroshi
    Tanaka, Takaho
    Sueyoshi, Susumu
    Higashi, Hidefumi
    Matsuda, Hiroyuki
    Touyama, Tetsuo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 110 - 117
  • [27] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [28] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [29] SUNITINIB PLUS 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MFOLFOX6) VS. BEVACIZUMAB PLUS MFOLFOX6 IN FRST-LINE METASTATIC COLORECTAL CANCER (MCRC) - INTERIM RESULTS OF A RANDOMIZED, PHASE IIB STUDY
    Hecht, J.
    Yoshino, T.
    Mitchell, E.
    Dees, M.
    Kroening, H.
    Patel, R.
    Welslau, M.
    Dakhil, S.
    Yamazaki, K.
    Maneval, Chow E.
    Kretzschmar, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [30] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
12345